@FierceBiotech: U.K. to digitize patient health records and sell access to biopharma researchers. Story from FierceBiotech IT | Follow @FierceBiotech
@JohnCFierce: U.K. group looks to ignite a Boston-style biotech comeback. More | Follow @JohnCFierce
@DamianFierce: Reminder that FierceBiotech's annual list of the most influential people in biopharma is now (somewhat) democratic. More | Follow @DamianFierce
@EmilyMFierce: This map of vaccine-preventable diseases is pretty striking. Map | Follow @EmilyMFierce
> Ireland's Prothena picked up a $30 million milestone payment from Roche with the launch of their collaboration on PRX002, an early-stage Parkinson's drug. Release
> Celladon has filed an amended S-1, reviving its plan to launch an IPO. Story
> The U.K.'s Prosonix announced positive top-line results from its Phase II clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease. Release
@FierceMedDev: In 2013, eNeura won de novo approval in the U.S. for its anti-migraine device. Report | Follow @FierceMedDev
@MarkHFierce: Stryker grew net sales by 5.6% in Q4. Release | Follow @MarkHFierce
@MichaelGFierce: Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Quest Diagnostics inks $570M Solstas deal. Story | Follow @EmilyWFierce
> Covidien opens an Indian medical training center with a med tech focus. Article
> Varian touts emerging markets as looming Medicare changes take a toll. News
> Quest Diagnostics will pay $570M for another laboratory testing outfit. Item
> For Stryker, acquisitions began to generate financial benefits in late 2013. More
> Medtronic wins patent loss reversal in U.S. Supreme Court. Report
Pharma News
@FiercePharma: Biotechs trumpet pandemic vaccine deals and data as the H7N9 bird flu threat grows. Story from FierceVaccines | Follow @FiercePharma
@TracyStaton: Two top stories at FiercePharma yesterday are both RE Novartis job cuts. Swiss, with rehires (Story) and New York, with Novartis plant closing by 2017 (Story) | Follow @TracyStaton
@EricPFierce: Closing of US Lonza plant took a toll on its sales last quarter as expiring contracts were not renewed. Story from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: We're taking nominations for the 25 most influential people in biopharma for our annual report. Submit them here. Survey | Follow @CarlyHFierce
> Under investor pressure, Teva chairman pledges a smaller, more experienced board. Report
> With Iclusig back to market, would Eli Lilly bid for Ariad? Would anyone? Story
> Novo Nordisk quits South African pharma group over 'satanic' PR campaign. Article
Pharma Manufacturing News
> J&J consumer health boosts results, even without key plant. Story
> Par bolsters its sterile manufacturing with a $490M deal to grab JHP. Story
> New York plant that makes Diovan is next on Novartis' shutdown list. Story
> Glaxo is investing $200M in additions to its U.K. site. Story
> Lilly gets ready for track-and-trace in U.S. Item
> Lonza's pharma unit sales suffer as it closes U.S. biologics plant. Article
Vaccines News
> How vaccines helped India defeat polio while Pakistan became a reservoir for the virus. Story
> Study: Tightening vaccine exemption laws would cut cases of whooping cough. Story
> Map of vaccine-preventable diseases shows the scale of problems facing the West. Story
> Biotechs trumpet pandemic vaccine deals and data as the H7N9 bird flu threat grows. Story
> NIH backs New York MERS-CoV vaccine development program. Story
> The political causes of the Syrian polio crisis. Item